The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the TMPRSS6 (Transmembrane Protease, Serine 6) gene, and methods of using such dsRNA compositions to inhibit expression of TMPRSS6. Further disclosed are dsRNA sequences and pharmaceutical compositions comprising lipid formulation of the dsRNA and methods of using the dsRNA compositions for treating disorders associated with an increased expression of TMPRSS6.La présente invention concerne des compositions à base dacide ribonucléique double brin (ARNdb) ciblant le gène TMPRSS6, ainsi que des méthodes dutilisation desdites compositions à base dARNdb en vue de linhibition de lexpression du gène TMPRSS6.
